Skip to main content
MBX $55.94 +2.62%
MBX logo
MBX · MBX Biosciences, Inc.
Track MBX — free
$55.94 +1.43 (+2.62%) At close · Nov 13 Play latest call Q2 2025 earnings call transcript
Market Cap
$2.78B
Shares
49.66M
Volume · Nov 13 855.51K Avg daily vol (3M) 527.3K
All webcasts

Earnings call · FY2026 Q3

MBX Biosciences, Inc. (MBX) Q3 2026 Earnings Call

Concluded Nov 9, 2026
Nov 9, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Diluted EPS -$1.29
Net income -$62.42M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 9, 2026
MBX Biosciences began enrollment in the pivotal Phase 3 oPTimize trial of once-weekly canvuparatide. Cash and investments were $481.6 million at September 30, 2026, expected to fund operations into 2029; third-quarter net loss was $62.4 million.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document